Clinical Trials Logo
  1. Home
  2. Kidney Transplantation
  3. NCT01608412

A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus

Kidney Transplant Recipients Clinical Trial

Official title:
An Open-label Randomized Controlled Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus 3 Months After Kidney Transplantation.

Clinical Trial Summary

The study hypotheses to be tested in this study are:

- Conversion to everolimus at 3 months post-transplantation is safe and effective;

- Accurate noninvasive molecular diagnostic tests can replace biopsy at 3 months pre-conversion (for the diagnosis of subclinical cellular and/or humoral rejection, tissue fibrosis and calcineurin inhibitor-induced nephrotoxicity) in kidney transplant recipients;

- Follow-up biopsy at 12 months post-conversion (for the diagnosis of tissue fibrosis) can be replaced with accurate noninvasive molecular diagnostic tests in kidney transplant recipients.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01608412
Study type Interventional
Source Hospital de Clinicas de Porto Alegre
Contact Luiz Felipe S. Gonçalves, MD
Email lfgoncalves@hcpa.ufrgs.br
Status Recruiting
Phase Phase 4
Start date February 2012
Completion date July 2014
View Details
See also
  Status Clinical Trial Phase
Completed NCT01336296 - Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients Phase 4
Recruiting NCT05938712 - The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients Phase 2
Completed NCT00217100 - A Multivitamin Comparison Study in Kidney Transplant Recipients. Phase 3
Active, not recruiting NCT00199667 - Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients Phase 4
Terminated NCT01517984 - Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation Phase 2
Recruiting NCT04642833 - Prostate Cancer in Renal Transplants Recipients
Not yet recruiting NCT05293704 - An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients Phase 4
Completed NCT02555566 - Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study N/A
Completed NCT01782586 - Validation of Gene Expression Markers of Renal Allograft Functional Decline
Enrolling by invitation NCT02042963 - KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT) N/A
Not yet recruiting NCT05702398 - Pilot Trial of Supplemental Vitamin A and Nicotinamide Early Phase 1
Recruiting NCT05425498 - The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients N/A
Completed NCT01889758 - Pharmacokinetic Studies of Tacrolimus in Transplant Patients Phase 4
Terminated NCT02268201 - A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule Phase 4
Active, not recruiting NCT03979365 - Envarsus XR Compared to Immediate Release Tacrolimus Phase 4
Recruiting NCT04965935 - Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients Phase 3
Recruiting NCT04444843 - Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen Phase 4
Completed NCT02392312 - Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
Completed NCT02639949 - Measuring and Improving Medication Adherence in Kidney Transplant Patients N/A
Withdrawn NCT02058875 - Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring Phase 4